Johnson & Johnson: COVID-19 vaccine is 66% effective overall in global trial
|Johnson & Johnson announced on Friday that its COVID-19 vaccine was 66% effective overall in the global trial, as reported by Reuters. The company further noted that the vaccine was 72% effective in the US portion of the trial.
Market reaction
This headline seems to be weighing heavily on market sentiment. As of writing, the S&P 500 Futures were down 1.2% on a daily basis. Meanwhile, Germany's DAX 30 was losing 1.35% and the UK's FTSE 100 was falling 1.9%.
Additional takeaways
"Vaccine is 57% effective in South Africa portion of trial."
"Vaccine is 85% effective overall in preventing severe disease."
"Single-dose covid vaccine was generally well tolerated."
"Looking to file in early February for US Emergency Use Authorization."
"Will have vaccine ready to ship immediately following authorization."
"Expecting to meet 2021 vaccine supply commitments."
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.